Andrew Lumsden Buys 100,000 Shares of PolyNovo (ASX:PNV) Stock

PolyNovo Limited (ASX:PNV) insider Andrew Lumsden acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, February 24th. The stock was acquired at an average price of A$0.91 per share, with a total value of A$91,400.00.

PolyNovo Price Performance

The company has a market cap of $1.30 billion, a PE ratio of 247.31, a price-to-earnings-growth ratio of 2.63 and a beta of 1.67. The company has a current ratio of 3.41, a quick ratio of 1.58 and a debt-to-equity ratio of 21.32.

PolyNovo Company Profile

PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell Implant to host pancreatic islet cells in the skin; NovoSorb MTX for the treatment of varying complex wounds; and plastics and reconstructive device product.